Growth stimulation expressed gene 2 (ST2): Clinical research and application in the cardiovascular related diseases

Growth stimulation expressed gene 2 (ST2): Clinical research and application in the cardiovascular related diseases

As an interleukin (IL)-1 receptor family member, scientists found that when circulating soluble growth stimulation expressed gene 2 (sST2) is low, its ligand, IL-33, will bind to ST2L to exert protective effects on various types of cells. On the other hand, competitive binding of IL-33 occurs when s...

Full description

Bibliographic Details
Main Authors:	Jinchao Chen, Peng Xiao, Dan Song, Dewei Song, Zhi Chen, Hongmei Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	biomarker sST2 cardiovascular disease diagnosis clinical testing traceability
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.1007450/full

Similar Items

Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)
by: Dongqing Chen, et al.
Published: (2023-04-01)

Soluble ST2 Is a Sensitive and Specific Biomarker for Fulminant Myocarditis
by: Jin Wang, et al.
Published: (2022-04-01)

sST2 and Heart Failure—Clinical Utility and Prognosis
by: Magdalena Dudek, et al.
Published: (2023-04-01)

The Prognostic Role of ST2L and sST2 in Patients Who Underwent Carotid Plaque Endarterectomy: A Five-Year Follow-Up Study
by: Pietro Scicchitano, et al.
Published: (2022-05-01)

Testosterone and soluble ST2 as mortality predictive biomarkers in male patients with sepsis-induced cardiomyopathy
by: Lu Wang, et al.
Published: (2024-01-01)

Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study
by: Martin Nicol, et al.
Published: (2023-08-01)

Elevated Sera sST2 Is Associated With Heart Failure in Men ≤50 Years Old With Myocarditis
by: Michael J. Coronado, et al.
Published: (2019-01-01)

Promising Novel Biomarkers in Cardiovascular Diseases
by: Brigitte Sipos, et al.
Published: (2021-04-01)

Soluble ST2 and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease—A 10-Year Cohort Study
by: Matthias H. Urban, et al.
Published: (2021-12-01)

Clinical Relevance of Elevated Soluble ST2, HSP27 and 20S Proteasome at Hospital Admission in Patients with COVID-19
by: Ralph Wendt, et al.
Published: (2021-11-01)

Circulating sST2 and prognosis of cardiovascular events in remission of multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-10-01)

Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance
by: Junyan Zhang, et al.
Published: (2022-09-01)

Prognostic Role of sST2 in Acute Heart Failure and COVID-19 Infection—A Narrative Review on Pathophysiology and Clinical Prospective
by: Luca Marino, et al.
Published: (2022-07-01)

Soluble ST2 in Patients with Carotid Artery Stenosis—Association with Plaque Morphology and Long-Term Outcome
by: Stefan Stojkovic, et al.
Published: (2023-05-01)

IL-33 and Soluble ST2 Are Associated With Recurrent Spontaneous Abortion in Early Pregnancy
by: Long Zhao, et al.
Published: (2022-01-01)

Analytical performances of a new rapid assay of soluble ST2 for cardiac and inflammatory diseases and establishment of the reference intervals for children and adolescence in China
by: Zhicheng Ye, et al.
Published: (2023-08-01)

Serum-soluble ST2 as a novel biomarker for COVID-19 severity and mortality: A systematic review and meta-analysis
by: Kacper DZIEDZIC, et al.
Published: (2024-03-01)

Study the correlation of FIB-4 and sST2 levels with heart failure
by: Tao Xuejiao, Lu Junkun, Chen Jiahui, Gao Yujin
Published: (2023-08-01)

sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation
by: Albert Topf, et al.
Published: (2021-11-01)

Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
by: Peter Jirak, et al.
Published: (2020-04-01)

Cardiovascular Biomarkers for Prediction of in-hospital and 1-Year Post-discharge Mortality in Patients With COVID-19 Pneumonia
by: Lukas J. Motloch, et al.
Published: (2022-06-01)

Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study
by: Victoria Dworok, et al.
Published: (2023-11-01)

Impact of Midregional N‐Terminal Pro–Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study
by: Marc Badoz, et al.
Published: (2021-07-01)

Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis
by: Florian F. Hildenbrand, et al.
Published: (2024-01-01)

Soluble ST2 Receptor: Biomarker of Left Ventricular Impairment and Functional Status in Patients with Inflammatory Cardiomyopathy
by: Danilo Momira Obradovic, et al.
Published: (2022-01-01)

Soluble St2 Induces Cardiac Fibroblast Activation and Collagen Synthesis via Neuropilin-1
by: Lara Matilla, et al.
Published: (2020-07-01)

Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases
by: Jin-xiu Lyu, et al.
Published: (2024-02-01)

Prognostic value of P-selectin and sST2 in patients with multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-11-01)

Soluble ST2 as a Potential Biomarker for Abdominal Aortic Aneurysms—A Single-Center Retrospective Cohort Study
by: Johannes Klopf, et al.
Published: (2022-08-01)

The role of fibrosis, inflammation, and congestion biomarkers for outcome prediction in candidates to cardiac resynchronization therapy: is “response” the right answer?
by: Matteo Beltrami, et al.
Published: (2023-06-01)

Soluble ST2 as a Useful Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients
by: Mikyoung Park, et al.
Published: (2023-01-01)

sST2 and Big ET-1 as Alternatives of Multi-Biomarkers Strategies for Prognosis Evaluation in Patients Hospitalized with Heart Failure
by: Chen Y, et al.
Published: (2023-11-01)

Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n’ Jill
by: Jianli Bi, et al.
Published: (2021-01-01)

The correlation between maternal serum sST2, IL‐33 and NT‐proBNP concentrations and occurrence of pre‐eclampsia in twin pregnancies: A longitudinal study
by: Qianqian Xiang, et al.
Published: (2022-11-01)

Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation
by: Javier García-Seara, et al.
Published: (2023-09-01)

In vitro diagnostic technologies for the detection of extracellular vesicles: current status and future directions
by: Shuya Song, et al.
Published: (2023-04-01)

The ST2/IL-33 Pathway in Adult and Paediatric Heart Disease and Transplantation
by: Giacomina Brunetti, et al.
Published: (2023-06-01)

Identification and validation of a novel ubiquitination-related gene UBE2T in Ewing’s sarcoma
by: Guoxin Qu, et al.
Published: (2023-02-01)

A Comparative Analysis of Novel Biomarkers in Sepsis and Cardiovascular Disease
by: Peter Jirak, et al.
Published: (2022-01-01)

The Role of Galectin-3 and ST2 in Cardiology: A Short Review
by: Ana Merino-Merino, et al.
Published: (2021-08-01)